Therefore, the use of new technological advances such as single cell RNA-seq can shed new light on the GLP-1RA-dependent and independent effects and targets in animal models and humans [177]
Toujeo typically causes weight gain because insulin promotes glucose uptake into cells, including fat cells, and reduces glucose loss through urine
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
Why Gut Barrier Support Differs From Digestive Probiotics Akkermansia vs Ozempic: Why Gut Balance May Shape GLP-1, Digestion, and Results 2 Comments Hi Donna, Thank you for sharing this what youre experiencing is actually quite common in the early weeks of tirzepatide
The medications covered include semaglutide (Wegovy), liraglutide (Saxenda) and tirzepatide (Zepbound)
Although these animal models (such as those employing chronic intermittent ethanol exposure paradigms) provide compelling mechanistic insights, extrapolation to human populations should be approached with caution, given interspecies physiological and behavioral differences
.png)
